TISIDB

Summary
Symbol	OS9
Name	osteosarcoma amplified 9, endoplasmic reticulum lectin
Aliases	OS-9; ERLEC2; endoplasmic reticulum lectin 2; erlectin 2; amplified in osteosarcoma 9; osteosarcoma amplifie ......
Chromosomal Location	12q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Endoplasmic reticulum lumen
Domain	PF07915 Glucosidase II beta subunit-like protein
Function	Lectin which functions in endoplasmic reticulum (ER) quality control and ER-associated degradation (ERAD). May bind terminally misfolded non-glycosylated proteins as well as improperly folded glycoproteins, retain them in the ER, and possibly transfer them to the ubiquitination machinery and promote their degradation. Possible targets include TRPV4.

> Gene Ontology [ TOP ]
Biological Process	GO:0006517 protein deglycosylation GO:0006621 protein retention in ER lumen GO:0009894 regulation of catabolic process GO:0009895 negative regulation of catabolic process GO:0010498 proteasomal protein catabolic process GO:0030433 ER-associated ubiquitin-dependent protein catabolic process GO:0030970 retrograde protein transport, ER to cytosol GO:0032386 regulation of intracellular transport GO:0032387 negative regulation of intracellular transport GO:0032507 maintenance of protein location in cell GO:0032527 protein exit from endoplasmic reticulum GO:0033157 regulation of intracellular protein transport GO:0034976 response to endoplasmic reticulum stress GO:0035437 maintenance of protein localization in endoplasmic reticulum GO:0036503 ERAD pathway GO:0036507 protein demannosylation GO:0036508 protein alpha-1,2-demannosylation GO:0042176 regulation of protein catabolic process GO:0042177 negative regulation of protein catabolic process GO:0042787 protein ubiquitination involved in ubiquitin-dependent protein catabolic process GO:0043161 proteasome-mediated ubiquitin-dependent protein catabolic process GO:0045185 maintenance of protein location GO:0051051 negative regulation of transport GO:0051220 cytoplasmic sequestering of protein GO:0051224 negative regulation of protein transport GO:0051235 maintenance of location GO:0051651 maintenance of location in cell GO:0070861 regulation of protein exit from endoplasmic reticulum GO:0070862 negative regulation of protein exit from endoplasmic reticulum GO:0070972 protein localization to endoplasmic reticulum GO:0072595 maintenance of protein localization in organelle GO:0090317 negative regulation of intracellular protein transport GO:1903513 endoplasmic reticulum to cytosol transport GO:1903573 negative regulation of response to endoplasmic reticulum stress GO:1903828 negative regulation of cellular protein localization GO:1904152 regulation of retrograde protein transport, ER to cytosol GO:1904153 negative regulation of retrograde protein transport, ER to cytosol GO:1904292 regulation of ERAD pathway GO:1904293 negative regulation of ERAD pathway GO:1904380 endoplasmic reticulum mannose trimming GO:1904950 negative regulation of establishment of protein localization
Molecular Function	GO:0001948 glycoprotein binding GO:0002020 protease binding GO:0030246 carbohydrate binding
Cellular Component	GO:0000151 ubiquitin ligase complex GO:0000153 cytoplasmic ubiquitin ligase complex GO:0000835 ER ubiquitin ligase complex GO:0000836 Hrd1p ubiquitin ligase complex GO:0005788 endoplasmic reticulum lumen GO:0044322 endoplasmic reticulum quality control compartment

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04141 Protein processing in endoplasmic reticulum
Reactome	R-HSA-5619084: ABC transporter disorders R-HSA-382556: ABC-family proteins mediated transport R-HSA-446203: Asparagine N-linked glycosylation R-HSA-901042: Calnexin/calreticulin cycle R-HSA-5678895: Defective CFTR causes cystic fibrosis R-HSA-1643685: Disease R-HSA-5663202: Diseases of signal transduction R-HSA-5619115: Disorders of transmembrane transporters R-HSA-901032: ER Quality Control Compartment (ERQC) R-HSA-5358346: Hedgehog ligand biogenesis R-HSA-5387390: Hh mutants abrogate ligand secretion R-HSA-5362768: Hh mutants that don't undergo autocatalytic processing are degraded by ERAD R-HSA-392499: Metabolism of proteins R-HSA-532668: N-glycan trimming in the ER and Calnexin/Calreticulin cycle R-HSA-597592: Post-translational protein modification R-HSA-162582: Signal Transduction R-HSA-5358351: Signaling by Hedgehog R-HSA-382551: Transmembrane transport of small molecules

> KEGG and Reactome Pathway

[ TOP ]

KEGG

hsa04141 Protein processing in endoplasmic reticulum

Reactome

R-HSA-5619084: ABC transporter disorders
R-HSA-382556: ABC-family proteins mediated transport
R-HSA-446203: Asparagine N-linked glycosylation
R-HSA-901042: Calnexin/calreticulin cycle
R-HSA-5678895: Defective CFTR causes cystic fibrosis
R-HSA-1643685: Disease
R-HSA-5663202: Diseases of signal transduction
R-HSA-5619115: Disorders of transmembrane transporters
R-HSA-901032: ER Quality Control Compartment (ERQC)
R-HSA-5358346: Hedgehog ligand biogenesis
R-HSA-5387390: Hh mutants abrogate ligand secretion
R-HSA-5362768: Hh mutants that don't undergo autocatalytic processing are degraded by ERAD
R-HSA-392499: Metabolism of proteins
R-HSA-532668: N-glycan trimming in the ER and Calnexin/Calreticulin cycle
R-HSA-597592: Post-translational protein modification
R-HSA-162582: Signal Transduction
R-HSA-5358351: Signaling by Hedgehog
R-HSA-382551: Transmembrane transport of small molecules

Summary
Symbol	OS9
Name	osteosarcoma amplified 9, endoplasmic reticulum lectin
Aliases	OS-9; ERLEC2; endoplasmic reticulum lectin 2; erlectin 2; amplified in osteosarcoma 9; osteosarcoma amplifie ......
Chromosomal Location	12q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between OS9 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	OS9
Name	osteosarcoma amplified 9, endoplasmic reticulum lectin
Aliases	OS-9; ERLEC2; endoplasmic reticulum lectin 2; erlectin 2; amplified in osteosarcoma 9; osteosarcoma amplifie ......
Chromosomal Location	12q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of OS9 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.55	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	OS9
Name	osteosarcoma amplified 9, endoplasmic reticulum lectin
Aliases	OS-9; ERLEC2; endoplasmic reticulum lectin 2; erlectin 2; amplified in osteosarcoma 9; osteosarcoma amplifie ......
Chromosomal Location	12q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of OS9 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.398	0.158
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	-0.347	0.92
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.429	0.859
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.236	0.431
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.192	0.944
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.29	0.932
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.139	0.789
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.119	0.958
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.118	0.963
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.389	0.883
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.751	0.848
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.054	0.43

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of OS9 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	14.8	2.7	12.1	0.0439
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	14.8	3.4	11.4	0.0746
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	0	0	0	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	0	0	0	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	7.7	-7.7	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	8.3	-8.3	1

Summary
Symbol	OS9
Name	osteosarcoma amplified 9, endoplasmic reticulum lectin
Aliases	OS-9; ERLEC2; endoplasmic reticulum lectin 2; erlectin 2; amplified in osteosarcoma 9; osteosarcoma amplifie ......
Chromosomal Location	12q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of OS9. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	OS9
Name	osteosarcoma amplified 9, endoplasmic reticulum lectin
Aliases	OS-9; ERLEC2; endoplasmic reticulum lectin 2; erlectin 2; amplified in osteosarcoma 9; osteosarcoma amplifie ......
Chromosomal Location	12q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of OS9. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by OS9. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	OS9
Name	osteosarcoma amplified 9, endoplasmic reticulum lectin
Aliases	OS-9; ERLEC2; endoplasmic reticulum lectin 2; erlectin 2; amplified in osteosarcoma 9; osteosarcoma amplifie ......
Chromosomal Location	12q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of OS9. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	OS9
Name	osteosarcoma amplified 9, endoplasmic reticulum lectin
Aliases	OS-9; ERLEC2; endoplasmic reticulum lectin 2; erlectin 2; amplified in osteosarcoma 9; osteosarcoma amplifie ......
Chromosomal Location	12q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of OS9 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	OS9
Name	osteosarcoma amplified 9, endoplasmic reticulum lectin
Aliases	OS-9; ERLEC2; endoplasmic reticulum lectin 2; erlectin 2; amplified in osteosarcoma 9; osteosarcoma amplifie ......
Chromosomal Location	12q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between OS9 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	OS9
Name	osteosarcoma amplified 9, endoplasmic reticulum lectin
Aliases	OS-9; ERLEC2; endoplasmic reticulum lectin 2; erlectin 2; amplified in osteosarcoma 9; osteosarcoma amplifie ......
Chromosomal Location	12q13
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting OS9 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse OS9